[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

Brüssow, 2021 - Google Patents

Clinical trials with antiviral drugs against COVID‐19: some progress and many shattered hopes

Brüssow, 2021

View PDF
Document ID
403905272376099197
Author
Brüssow H
Publication year
Publication venue
Environmental Microbiology

External Links

Snippet

Vaccines and drugs are the cornerstones in the fight against the SARS‐CoV‐2 pandemic. While vaccines were a success story, the development of antiviral drugs against SARS‐CoV‐ 2 turned out to be difficult. For an accelerated use of antivirals in the clinic, most SARS‐CoV …
Continue reading at enviromicro-journals.onlinelibrary.wiley.com (PDF) (other versions)

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • G—PHYSICS
    • G06—COMPUTING; CALCULATING; COUNTING
    • G06F—ELECTRICAL DIGITAL DATA PROCESSING
    • G06F21/00—Security arrangements for protecting computers, components thereof, programs or data against unauthorised activity
    • G06F21/50—Monitoring users, programs or devices to maintain the integrity of platforms, e.g. of processors, firmware or operating systems
    • G06F21/55—Detecting local intrusion or implementing counter-measures
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof

Similar Documents

Publication Publication Date Title
Jayk Bernal et al. Molnupiravir for oral treatment of Covid-19 in nonhospitalized patients
Mukae et al. Efficacy and safety of ensitrelvir in patients with mild-to-moderate coronavirus disease 2019: the phase 2b part of a randomized, placebo-controlled, phase 2/3 study
Brüssow Clinical trials with antiviral drugs against COVID‐19: some progress and many shattered hopes
Fischer et al. A phase 2a clinical trial of molnupiravir in patients with COVID-19 shows accelerated SARS-CoV-2 RNA clearance and elimination of infectious virus
Aleem et al. Emerging variants of SARS-CoV-2 and novel therapeutics against coronavirus (COVID-19)
Dhawan et al. Delta variant (B. 1.617. 2) of SARS-CoV-2: Mutations, impact, challenges and possible solutions
Stiver The treatment of influenza with antiviral drugs
Khan et al. The emergence of new SARS-CoV-2 variant (Omicron) and increasing calls for COVID-19 vaccine boosters-The debate continues
Chaplin COVID‐19: a brief history and treatments in development
Bhat et al. SARS-CoV-2: insight in genome structure, pathogenesis and viral receptor binding analysis–an updated review
Sulkowski et al. Efficacy and safety of 8 weeks versus 12 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin in patients with hepatitis C virus genotype 1 mono-infection and HIV/hepatitis C virus co-infection (C-WORTHY): a randomised, open-label phase 2 trial
Reading et al. Increased susceptibility of diabetic mice to influenza virus infection: compromise of collectin-mediated host defense of the lung by glucose?
Buchy et al. COVID-19 pandemic: lessons learned from more than a century of pandemics and current vaccine development for pandemic control
Yuen et al. Efficacy and safety of the siRNA JNJ-73763989 and the capsid assembly modulator JNJ-56136379 (bersacapavir) with nucleos (t) ide analogues for the treatment of chronic hepatitis B virus infection (REEF-1): a multicentre, double-blind, active-controlled, randomised, phase 2b trial
Pagliano et al. Experimental pharmacotherapy for COVID-19: the latest advances
Ko et al. Emergence of SARS-CoV-2 spike mutations during prolonged infection in immunocompromised hosts
Herman et al. Efficacy and safety of a single dose of casirivimab and imdevimab for the prevention of COVID-19 over an 8-month period: a randomised, double-blind, placebo-controlled trial
Meshram et al. Feasibility and safety of remdesivir in SARS‐CoV2 infected renal transplant recipients: a retrospective cohort from a developing nation
Gupta et al. Effect of the neutralizing SARS-CoV-2 antibody sotrovimab in preventing progression of COVID-19: a randomized clinical trial
Hossain et al. Clinical efficacy and safety of antiviral drugs in the extended use against COVID-19: what we know so Far
Sullivan et al. Outpatient randomized controlled trials to reduce COVID‐19 hospitalization: Systematic review and meta‐analysis
Tsai et al. Clinical effectiveness of oral antiviral agents in older patients with COVID‐19 based on real‐world data
AL-Khikani COVID-19: Containment strategies and management options
Testino et al. Alcohol use disorder in the COVID‐19 era: Position paper of the Italian Society on Alcohol (SIA)
Marks et al. COVID-19